Skip to content
← Back to this collection

PUBLICATIONS · 27382093

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2016 Sep 1
First author
Héritier S

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Héritier S
      type
      Author
    2. name
      Emile JF
      type
      Author
    3. name
      Barkaoui MA
      type
      Author
    4. name
      Thomas C
      type
      Author
    5. name
      Fraitag S
      type
      Author
    6. name
      Boudjemaa S
      type
      Author
    7. name
      Renaud F
      type
      Author
    8. name
      Moreau A
      type
      Author
    9. name
      Peuchmaur M
      type
      Author
    10. name
      Chassagne-Clément C
      type
      Author
    11. name
      Dijoud F
      type
      Author
    12. name
      Rigau V
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Héritier S
      type
      Author
    2. name
      Emile JF
      type
      Author
    3. name
      Barkaoui MA
      type
      Author
    4. name
      Thomas C
      type
      Author
    5. name
      Fraitag S
      type
      Author
    6. name
      Boudjemaa S
      type
      Author
    7. name
      Renaud F
      type
      Author
    8. name
      Moreau A
      type
      Author
    9. name
      Peuchmaur M
      type
      Author
    10. name
      Chassagne-Clément C
      type
      Author
    11. name
      Dijoud F
      type
      Author
    12. name
      Rigau V
      type
      Author
    bibliography ids
    1. nci-bib-52ec7ffb6acafdcc9f6519c9
    book metadata
    content sha256
    63841da17475e8263573b4479214d421753b97e3f182a20254fb030b63a1244e
    document type
    citation
    dois
    1. 10.1200/JCO.2015.65.9508
    electronic publication date
    display
    2016 Jul 5
    precision
    day
    year
    2016
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:27382093
    immutable id
    pubmed:27382093@63841da17475e8263573b4479214d421753b97e3f182a20254fb030b63a1244e
    journal
    abbreviation
    J Clin Oncol
    issn electronic
    1527-7755
    issn print
    0732-183X
    issue
    25
    name
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    nlm unique id
    8309333
    pages
    3023-30
    volume
    34
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      27382093
      provenance
      batch id
      d649bcb2d98dbbacd53c
      provider
      NCBI PubMed ESummary
      record sha256
      b0be30774b23a758d6b126b329e2998f7eda0a9b8fdeec14a9e4944efca32ede
      response sha256
      26648a40f123f366675007f51cc29befd1f9a89273ca2da87c477c54d2d15d20
      retrieved at
      2026-09-09T23:47:20.761544+00:00
      publication date
      display
      2016 Sep 1
      precision
      day
      year
      2016
      publication types
      1. Journal Article
      2. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/27382093/
      title
      BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.

      Preserved source evidence · Independent clinical review pending · Not medical advice